An interventional study of STOP-HPV-Online and STOP-HPV-LC in Human Papilloma Virus Vaccine, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Papilloma with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Papilloma · United States.
Among the 51 studies in Papilloma with a site in United States, this one has the largest planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 27 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 46th registered.
89 studies on the registry are indexed under Papilloma; 20 are open to participants now.
Browse Papilloma studies →9 of the 51 studies in Papilloma with a site in United States are open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 30–65 · Women only · Healthy volunteers
Daré Bioscience, Inc. · Sites in United States
Ages 22–50 · Women only
Mel Mont Medical · Sites in United States
Ages 25–65 · Women only · Healthy volunteers
Case Comprehensive Cancer Center · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18–70 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Papilloma studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 9 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 4 3
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100,000 is above the median of 118 across 65 interventional studies indexed under Papilloma.
Median enrollment 155 across the 39 interventional studies, 155 across the 12 observational. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 51 have an industry lead sponsor. The 10 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
University of California, Los Angeles has 1 study filed under Papilloma — fewer than ten, so there is no comparison to draw.
7 of the studies in Papilloma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07758140Mel Mont MedicalComparative Self-collection for Cervical Cancer Screening Pivotal Study | 2026-12 |
| NCT07060261Case Comprehensive Cancer CenterPre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma | 2026-12 |
| NCT06624839University of Maryland, BaltimoreEvaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV | 2027-01 |
| NCT06831383University of California, Los AngelesThe STOP-HPV Scale Up Study | 2027-04-19 |
| NCT07657104Rutgers, The State University of New JerseyDeveloping and Implementing HPV SCREENED | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 51 studies in Papilloma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost effectiveness of two potentially scalable implementation strategies (based on prior work) to increase the initiation of HPV vaccine against a usual care (control) arm. The intervention arms are 1) online provider communication training only ("STOP-HPV-Online" and 2) online provider communication training plus a Learning Collaborative, with performance feedback, attended by practice leads ("STOP-HPV-LC).
cer-related costs. It is recommended at ages 11-12 years routinely but can be given starting at ages 9-10 years. Despite having an effective vaccine, HPV vaccine initiation/completion rates in the U.S. were only at 76.8%/61.4% respectively in 2023 among 13-17 year olds; these rates are lower than the other recommended adolescent vaccines. Two key barriers are 1) suboptimal clinician communication to address parental concerns and 2) ineffective office systems causing missed vaccine opportunities.
In prior work, the investigators have tested two implementation strategies/interventions that were effective, but which were deployed by the research team. The first is provider communication training ("STOP-HPV-Online"), delivered by the research team, in a cluster RCT in 48 pediatric practices from a research network (6.8% improvement in initiation). The other is a quality improvement, pre-post study, that included both provider communication training, as well as a Learning Collaborative (LC) for practice leads (8% increase in initiation).
A major challenge in implementation science and spreading practice-based strategies is to move from research teams deploying implementation strategies (intervention) to health systems deploying them. In this study, the investigators will compare the effectiveness and cost-effectiveness of the two implementation strategies (interventions) using a 3-arm clustered RCT: 1) STOP-HPV-Online vs 2) STOP-HPV-LC vs 3) usual care. The study team will randomize an estimated 72 practices (from up to 8 health systems) to the 1) STOP-HPV-Online arm, 2) the STOP-HPV-LC arm or 3) the control arm, assess fidelity to the intervention and conduct the evaluation. A collaborating organization, AMGA (the American Medical Group Association), will facilitate training of the health system personnel, as needed; however, the health systems will deploy each intervention. The primary outcome measure is the initiation rate among 9-\<13 year olds with a well-child care visit during the 12 month intervention period (with inclusion starting at the time of a well child care visit during the intervention period). A secondary outcome measure will be the initiation rate among 13-17 year olds with a well child care visit during the intervention period (with inclusion starting at the time of a well child care visit during the intervention period. For both measures, inclusion criteria will be: 1) presenting to a participating practice, 2) age eligible at the visit and 3) no prior vaccine at the time of the visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Provider communication training
Behavioral: STOP-HPV-Online
Provider communication training plus Learning Collaborative sessions attended by practice leads and quarterly performance feedback to the practice.
Behavioral: STOP-HPV-LC
Standard of care control
Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-Online intervention.
Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-LC intervention.
Initiation (first dose) of HPV vaccination among 9-<13 year olds at or following a well care visit with a participating provider during the intervention period.
The percent of children ages 9-\<13 years of age who received their first dose of HPV vaccine at or following a well child care visit with a participating provider during the intervention-period (denominator is children ages 9-\<13 with a well child visit during the study period at which they were due for their first dose).
Time frame: 12 months from start of intervention
Initiation (first dose) of HPV vaccination among 13-17 year olds at or following a well care visit with a participating provider during the intervention period.
The percent of children ages 13-17 years of age who received their first dose of HPV vaccine at or following a well child care visit with a participating provider during the intervention-period (denominator is children ages 13-17 years with a well child visit during the study period at which they were due for their first dose).
Time frame: 12 months from start of intervention
Initiation (first dose) of HPV vaccination among 9-<13 year olds at or following a well care visit with any provider during the intervention period.
The percent of children ages 9-\<13 years of age who received their first dose of HPV vaccine at or following a well child care visit with any provider (participating or not) during the intervention-period (denominator is children ages 9-\<13 with a well child visit during the study period at which they were due for their first dose).
Time frame: 12 months from start of intervention
Initiation (first dose) of HPV vaccination among 13-17 year olds at or following a well care visit with any provider during the intervention period.
The percent of children ages 13-17 years of age who received their first dose of HPV vaccine at or following a well child care visit with any provider (participating or not) during the intervention-period (denominator is children ages 13-17 years with a well child visit during the study period at which they were due for their first dose).
Time frame: 12 months from start of intervention
Total implementation cost
The difference in costs between arms will be used to calculate the incremental cost-effectiveness ratio (ICER)
Time frame: 12 months from start of intervention
Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
Of 28 interventional studies with no phase under Papilloma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles →